Clinical

核心通过招募、注册和纵向支持成人子女学习计划项目赠款 跟随父母患有和不患有阿尔茨海默病的父母的成年子女，年龄45-74岁 (DAT)。45岁-将在入院时和每隔两天进行临床和心理测量评估 之后的几年(对于ACS参与者，每年一次；65年)。核心是必不可少的，因为它仔细地供应 将参与者描述为所有相关的核心和项目。核心人员将核心数据录入到 由数据管理和生物统计核心(DMBC)维护的数据库。临床核心 每天直接或间接地与ACS PPG的几乎每一个方面进行互动。 核心的职能是： 1.招募、登记和维护ACS队列，以支持此应用程序中的项目。在头两年 在拨款中，核心将招收60名ACS参与者，以补偿自然减员并带来总样本 约300名参与者平均分布在3个年龄段：45-54岁，55-岁，65-74岁。 在接下来的3年里，临床核心中心将每年招聘约5000名参与者，以维持 约300名活跃参与者的注册。 2.用成熟的临床和心理测量学对ACS参与者进行全面评估 入场时和每两年一次(65岁的参与者每年一次)。 3.在所有参与者进行载脂蛋白E(ApoE)基因分型的初步评估中采集血液，并 储存提取的DNA和血浆(由ADRC的遗传学核心支持)。 4.协调ACS参与者参与生物标志核心和所有项目的程序： (项目1--临床前阿尔茨海默病患者AP蓄积的自然历史。项目2--先证者的脑脊液标志物 项目3--注意控制的行为和神经标记物；AD的前驱因素；项目4- 先期神经成像生物标志物。) 5.将所有核心数据与DMBC集成，并与PPG的所有组件进行协同交互。 6.通过保护他们的研究数据、监测 参与者在完成核心和项目协议时的负担，每年与他们分担 研究结果，并征求他们对ACS的目标和运作的意见。

The Core supports the Adult Children Study Program Project Grant by recruiting, enrolling and longitudinally following adult children, age 45-74 years at entry, of parents with and without dementia of the Alzheimer type (DAT). ACS participants age 45-64 will have clinical and psychometric assessments at entry and every 2 years thereafter (annually for ACS participants >65y). The Core is essential in that it supplies carefully characterized participants to all relevant Cores and Projects. Core data are entered by Core personnel into the database maintained by the Data Management and Biostatistics Core (DMBC). The Clinical Core interacts directly or indirectly on a daily basis with virtually every facet of the ACS PPG. The functions of the Core are to: 1. Recruit, enroll, and maintain the ACS cohort to support the Projects in this application. In the first 2 years of the grant, the Core will enroll 60 ACS participants to compensate for attrition and to bring the total sample to ~300 participants equally distributed across 3 age ranges: 45-54 years, 55-64 years, and 65-74 years. The following 3 years the Clinical Core will recruit an estimated 5 participants annually to maintain the registry of ~300 active participants. 2. Comprehensively assess the ACS participants with well-established clinical and psychometric instruments at entry and every two years (annually for participants >65 years of age). 3. Obtain blood at the initial assessment from all participants for apolipoprotein E (apoE) genotyping and banking of extracted DNA and plasma (supported by the Genetics Core of the ADRC). 4. Coordinate the participation of ACS participants in the procedures of the Biomarker Core and all Projects: (Project 1 - The natural history of Ap accumulation in preclinical AD. Project 2 - CSF markers of antecedent AD; Project 3 - Behavioral and Neural Markers of Attentional Control; Antecedents of AD; Project 4 - Antecedent Neuroimaging Biomarkers.) 5. Integrate all core data with the DMBC, and interact cooperatively with all components of the PPG. 6. Encourage the retention of ACS participants by safeguarding their research data, monitoring the participants' burden as they complete the protocols of the Cores and Projects, annually sharing with them research results, and soliciting their input into the aims and operations of the ACS.